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Abstract
Respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD) are characterised by
excessive and persistent inflammation. Current treatments are often inadequate for symptom and disease control,
and hence new therapies are warranted. Recent emerging research has implicated dyslipidaemia in pulmonary
inflammation. Three ATP-binding cassette (ABC) transporters are found in the mammalian lung – ABCA1, ABCG1
and ABCA3 – that are involved in movement of cholesterol and phospholipids from lung cells. The aim of this
review is to corroborate the current evidence for the role of ABC lipid transporters in pulmonary lipid homeostasis
and inflammation. Here, we summarise results from murine knockout studies, human diseases associated with ABC
transporter mutations, and in vitro studies. Disruption to ABC transporter activity results in lipid accumulation and
elevated levels of inflammatory cytokines in lung tissue. Furthermore, these ABC-knockout mice exhibit signs of
respiratory distress. ABC lipid transporters appear to have a crucial and protective role in the lung. However, our
knowledge of the underlying molecular mechanisms for these benefits requires further attention. Understanding
the relationship between cholesterol and inflammation in the lung, and the role that ABC transporters play in this
may illuminate new pathways to target for the treatment of inflammatory lung diseases.
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Background
Asthma and chronic obstructive pulmonary disease
(COPD) affect over 500 million people worldwide, con-
tributing to significant morbidity and mortality [1, 2].
These chronic lung diseases share many features, includ-
ing airway obstruction, persistent airway inflammation,
and presence of multiple inflammatory mediators.
However, the underlying pathophysiological processes
and responses to therapy for each disease are distinct
[3]. The pathogenesis of asthma involves secretion of
pro-inflammatory cytokines from airway epithelial cells
and macrophages [4], resulting in airway infiltration of
CD4+ T-lymphocytes, mast cells and eosinophils. Con-
trastingly, CD8+ T-lymphocytes, macrophages and neu-
trophils are the more predominant cell-types found in
lung tissue of patients with COPD [5]. Currently, bron-
chodilators including beta-agonists and anti-cholinergics,
and anti-inflammatory corticosteroids are the mainstays
of treatment. However, lack of disease-modifying effects of
and poor responses to these therapies mean that alternate
therapeutic targets and drugs are needed.
Inflammation is a complex response of the immune
system to tissue injury or foreign bodies. Whilst this is
considered a beneficial protective mechanism in assist-
ing restoration of normal tissue function, persistent and
excessive inflammatory responses may eventuate in dis-
ease. Recently, studies have implicated dyslipidaemia in
pulmonary inflammation and various lung pathologies
[6] and alongside, statins (3-hydroxymethyl-3-glutaryl
coenzyme A (HMG-CoA) reductase inhibitors) have
been tried as therapies for asthma and COPD with vary-
ing results [7–9].
Reverse cholesterol transport (RCT) is a protective
mechanism for regulating lipid homeostasis, acting to
shuttle excess cholesterol to the liver for subsequent
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excretion from the body. Essential to this mechanism is
the interplay between ATP-binding cassette (ABC)
transporters and extracellular lipid acceptors such as
high-density lipoproteins (HDL) [10, 11]. Currently, 48
ABC transporters have been identified that facilitate the
movement of a diverse range of substrates across cellular
membranes [12]. Three ABC lipid transporters, ABCA1,
ABCG1 and ABCA3, are expressed in mammalian lung
cells. The first two contribute to RCT by mediating
cellular cholesterol and phospholipid efflux and are
transcriptionally regulated by liver X receptors (LXRs)
[10, 11, 13]. ABCA3, a phospholipid exporter, is specif-
ically involved in pulmonary surfactant production.
Surfactants in the lung contain approximately 90%
phospholipids and 10% surfactant proteins and are es-
sential to prevent alveolar collapse by reducing surface
tension at the air-liquid interface [14, 15]. Studies in
lungs of knockout mice have established that absence
of ABC transporters result in disrupted lipid homeo-
stasis, diminished surfactant production, impaired
respiratory physiology and increased expression of in-
flammatory cytokines in lung cells [10, 15, 16]. Fur-
thermore, mutations to these transporter genes are
associated with human lung diseases such as alveolar
proteinosis and respiratory distress syndrome [14, 17,
18]. Given that hyperlipidaemia has been demonstrated
to accelerate inflammation in murine bronchoalveolar
lavages [19], the role of ABC transporters in the patho-
genesis of inflammatory lung diseases is an exciting
and promising avenue to explore.
This review will explore current available knowledge
regarding the roles of ABCA1, ABCG1 and ABCA3 in
maintaining lipid homeostasis and controlling inflamma-
tion in the lung. Clarifying this relationship between pul-
monary lipidosis and inflammation will help guide
relevant future research studies that could ultimately
identify an alternative therapeutic angle for the treat-
ment of asthma, COPD and other related conditions.
ABCA1
ABCA1 is widely expressed throughout the body and
contributes to RCT by exporting cholesterol and phos-
pholipids out of cells to extracellular acceptors [20, 21].
In the periphery, the lipid-poor HDL protein component
apolipoprotein (apo)A-I, is the predominant extracellular
acceptor, and binding of apoA-I to cells expressing
ABCA1 leads to the generation of small nascent HDL
particles [22, 23]. Homozygous and heterozygous muta-
tions to the ABCA1 alleles result in Tangier disease and
familial hypoalphalipoproteinaemia respectively, with
only around 100 Tangier patients diagnosed worldwide
[24]. Phenotypically, these patients have markedly re-
duced HDL levels, resulting in lipid accumulation in
numerous tissues and subsequent increased risks of
atherosclerosis and cardiovascular complications [25].
Furthermore, it was recently shown that ABCA1-
mutation carriers exhibit signs of systemic inflamma-
tion as indicated by elevated levels of circulating
inflammatory cytokines [24]. Over 73 mutations, in-
cluding single nucleotide polymorphisms have also
been reported in the ABCA1 gene [26], raising the pos-
sibility of more widespread cholesterol metabolic dis-
ruptions across populations. The contributions of such
mutations to development of asthma and COPD are yet
to be explored.
ABCA1 tissue expression is second highest in the
lungs, after the liver, suggesting a critical role for the
transporter and lipid homeostasis in pulmonary func-
tion [27]. Immunohistochemical data have identified
the presence of ABCA1 in alveolar type I (ATI) and
type II (ATII) pneumocytes and alveolar macrophages
[28, 29] (see Table 1 and Fig. 1). Cholesterol loading
and treatment with LXR-agonists, both separately and
conjointly, were also able to induce ABCA1 expression
and function in human airway smooth muscle (ASM)
cells [30].
Phenotype of ABCA1-knockout mouse models
The critical role of ABCA1 in lung inflammation is evi-
dent from murine knockout models. Abca1-knockout
mice exhibit interrupted lipid export, and a 70% reduc-
tion in plasma cholesterol and phospholipids due to vir-
tually undetectable HDL and apoA-I levels, compared to
wild-type [10]. Phenotypically, these mice at 4 months of
age exhibit massive cholesterol and phospholipid accu-
mulation in alveolar macrophages and ATII pneumo-
cytes, as compared with wild-type littermates [10].
Furthermore, oil red-O staining of Abca1−/− lungs
revealed pulmonary focal lesions, and microscopic ana-
lysis revealed enlarged foamy alveolar macrophages and
ATII cell hyperplasia, indicating alveolar proteinosis
[10]. Physiologically, these mice experienced reduced
tidal volume and hyperventilation, although it was un-
clear whether this respiratory distress was directly attrib-
utable to abnormalities in the lung or in other organs
[10]. Nevertheless, these findings, coupled with similar
but progressively severe observations in 7-, 12- and 18-
month-old mice [31], suggest that absence of ABCA1
results in age-dependent progressive pulmonary disease.
Supporting the importance of this ABCA1-mediated
pathway in normal lung physiology is the finding that
apoA-I−/− mice have elevated inflammatory cell infiltra-
tion (particularly neutrophils and leukocytes), collagen
deposition and airway hyper-responsiveness, and im-
paired pulmonary vasodilatation [32]. These observa-
tions strongly implicate a role of ABCA1-mediated RCT
in inflammatory lung diseases.
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Mechanisms of ABCA1-mediated RCT and role in
pulmonary inflammation
The mechanism by which ABCA1 exports lipids has
been predominantly studied in the context of its role in
macrophage lipid homeostasis and the development of
atherosclerosis. ABCA1 is thought to export lipids from
the inner to the outer leaflet of the cell membrane via
an ATP-dependent mechanism [12]. The subsequent
method of transfer of these lipids to apoA-I is still open
for debate. One model proposes that hydrolysis of ATP
causes a conformational change in the transporter, enab-
ling apoA-I to bind [33]; alternatively, apoA-I may bind
and solubilise lipids in exovesiculated membrane lipid
domains that arise from membrane asymmetry [34]. It is
worth noting that evidence for the presence of apoA-I in
the lung is currently limited. Bates and colleagues [28]
were able to stain cryosections of murine lungs with
anti-mouse apoA-I antibody, to verify that adequate
levels of apoA-I exist for interaction with pneumocyte
ABCA1. Meanwhile, Delvecchio and colleagues [30] per-
formed in vitro experiments involving incubation of
ASM cells with exogenous apoA-I, and were able to con-
firm the capacity of ASM ABCA1 to efflux lipids to
apoA-I. Of further interest was the finding that apoA-I
is reduced in sputum samples of patients with COPD
compared to controls (which were smokers), with the
authors suggesting that apoA-I could potentially be in-
vestigated as a biomarker [35]. Inhaled apoA-I mimetic
peptides, which are under development as treatments
for atherosclerosis, have been suggested as a potential
treatment for inflammatory lung conditions [36].
Studies addressing the mechanisms by which ABCA1
activity affects inflammatory processes in the lung have
investigated various pathways. Firstly, it has been pro-
posed that excess cholesterol itself is pro-inflammatory
and acts as the trigger for the cellular inflammatory re-
sponse [37], and hence ABCA1 activity may simply be
anti-inflammatory by removing excess cholesterol. Alter-
natively, other studies have investigated its transcrip-
tional upregulation via LXR. In human alveolar
macrophages, LXR-agonists that increased ABCA1
mRNA expression were shown to reduce LPS-induced
Table 1 Cellular expression and substrates of ABC transporters expressed in mammalian lungs
Transporter Expressed in which lung cells Reported substrates References
ABCA1 Alveolar macrophages, airway smooth muscle cells, type I




ABCG1 Alveolar macrophages, airway smooth muscle cells, type II









Fig. 1 ABC transporters expressed in various cell types of the alveolus. Three ABC transporters, namely ABCA1, ABCG1 and ABCA3, are expressed
in lung cells present in the alveolus, notably the alveolar epithelial type I and II cells (ATI and ATII respectively) that line the alveoli or air sacs, and
alveolar macrophages that are phagocytes of the pulmonary immune system. LB – lamellar bodies, where ABCA3 contributes lipids that
eventually are secreted as surfactants (represented via the black arrow)
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airway inflammation and neutrophil production. How-
ever, explanations for the underlying mechanisms are
conflicting. In one study, this was attributed to a NF-κB-
dependent pathway [38], whereas another study found
no involvement of either of the pro-inflammatory tran-
scription factors NF-κB or AP-1 [29]. However, it is
worthwhile noting that LXR also affects ABCG1 expres-
sion (covered in the next section), effects on which were
not accounted for in the latter study.
Lastly, Dai and colleagues have investigated effects of
ABCA1 overexpression in alveolar macrophages and
showed that the anti-inflammatory effects of ABCA1
may occur via suppression of granulocyte-colony stimu-
lating factor, which subsequently could reduce the in-
volvement of inflammatory cells such as neutrophils
[39]. Evidently, further research is required to clarify the
mechanisms by which ABCA1 activity affects inflamma-
tory pathways.
ABCA1 and asthma
The association between ABCA1 function and asthma
is still a novel and underdeveloped area. Mice overex-
pressing human ABCA1 exhibited reduced neutrophil
count, IgE levels, peri-bronchial inflammation and air-
way epithelial thickness in response to daily ovalbumin
challenges when compared to wildtype mice [39]. Fur-
thermore, treatment of house dust mite-challenged
mice with intranasal apoA-I was able to minimise eo-
sinophilia, neutrophilia, interleukin (IL)-17E, IL-33 and
airway hyperresponsiveness [40]. The same authors also
revealed that apoA-I levels in bronchoalveolar lavage
fluid of asthmatic patients were significantly lower than
that from healthy subjects [40]. These findings suggest
that upregulation of ABCA1 and/or apoA-I activity
could be beneficial in patients with inflammatory lung
diseases.
In summary, ABCA1 plays crucial roles in the main-
tenance of lipid homeostasis and modulation of inflam-
matory responses in lung cells. However, further studies
are necessary to elucidate the exact mechanisms by
which these effects occur and whether therapeutic tar-
geting of these pathways will be effective.
ABCG1
Like ABCA1, ABCG1 is also ubiquitously expressed in
the body [41]. ABCG1 is considered a half-transporter
and requires dimerization to be functional, unlike
ABCA1 which is a full-transporter that functions inde-
pendently [42]. Whereas ABCA1 contributes to forma-
tion of nascent HDL particles, ABCG1 is thought to
export lipids to larger, more mature HDL subclasses
[43]. It has been suggested from cell culture as well as
murine knockout models that ABCA1 and ABCG1 may
synergise together [42, 44].
ABCG1 has also mostly been studied in the context of
atherosclerosis, however there are currently no reported
genetic ABCG1 mutations reported that are associated
with an increased risk for cardiovascular disease in
humans. Interestingly, ABCG1 deficiency in human al-
veolar macrophages has been associated with pulmonary
alveolar proteinosis (PAP), a rare condition characterised
by accumulation of surfactant proteins and lipids in the
alveolar space [18]. This will be discussed in detail
below.
Similarly to ABCA1, ABCG1 utilises ATP to actively
export its substrates (see Table 1 and Fig. 1) to the exo-
plasmic leaflet of the cell membrane [42]. However, dir-
ect binding of ABCG1 with an acceptor (e.g. HDL) is
not required for transport activity, and there is currently
some debate in the literature whether the transporter is
exclusively located intracellularly or travels and acts on
the cell surface [45].
ABCG1 and its role in lipid homeostasis and pulmonary
inflammation
There is strong evidence derived from Abcg1-knockout
murine models to suggest that this transporter also plays
an essential role in maintaining pulmonary lipid homeo-
stasis. ABCG1 is widely expressed in various lung cell
types, including alveolar macrophages, epithelial cells,
ATII pneumocytes, ASM cells, T-lymphocytes and den-
dritic cells [43, 46, 47]. Several studies in Abcg1-knock-
out mice have demonstrated disrupted lipid homeostasis
in murine lungs. Compared to heterozygote Abcg1+/−
mice, homozygote knockouts revealed massive accumu-
lation of lipids in the alveolar macrophages. The sub-
pleural region of Abcg1−/− lungs also revealed build-up
of lymphocytes, multinucleated giant cells, and macro-
phage foam cells containing an abundance of cholesterol
clefts that indicated impaired lipid processing. These ob-
servations were progressive and age-dependent, and
were exacerbated upon administration of a high-fat
high-cholesterol diet [16, 43]. Furthermore, human
ABCG1-transgenic mice overexpressing the ABCG1
transporter were protected from this diet-induced pul-
monary lipidosis [43].
Absence of ABCG1 also results in progressive and
chronic pulmonary inflammation [19]. Immunofluores-
cence studies and bronchoalveolar lavages obtained from
chow-fed Abcg1−/− mice revealed multiple markers of in-
flammation, including elevated levels of foamy macro-
phages, lymphocytes and pro-inflammatory cytokines.
None of these features were observed in lungs of wild-
type littermates [19]. Coupled with the observations that
administration of a high-fat high-cholesterol diet signifi-
cantly accelerated lipid deposition and induced macro-
phage cytokine expression in wild-type and (to an even
greater extent in) Abcg1−/− lungs, these findings imply
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that ABCG1 indirectly controls inflammation by modify-
ing intracellular cholesterol levels [19]. However, the
timeline of events was less clear in a separate study,
which also reported inflammatory cytokine, neutrophil
and lymphocyte infiltration alongside lipidosis in the
lungs of Abcg1−/− mice [48]. Wojcik and coauthors pro-
posed that one of two mechanisms could be occurring:
i) lipid accumulation causes inflammation or ii) absence
of Abcg1 triggers inflammation that subsequently leads
to the observed lipidosis [48]; which one of these events
predominates is still unclear. Nevertheless, pulmonary
ABCG1 expression also appears to protect against ex-
ogenous inflammation-inducing factors. Abcg1−/− mice
challenged with LPS or gram-negative bacteria displayed
an exaggerated pulmonary response, characterised by
elevated neutrophil, leukocyte, cytokine and chemokine
levels in the airspace and tissue remodelling as com-
pared to wild-type mice [49]. These effects were attrib-
uted specifically to disrupted Abcg1−/− activity in
alveolar macrophages. Despite the enhanced pulmonary
bacterial clearance in these knockout mice, the exces-
sive inflammation meant they also had a much higher
mortality rate [49]. In a murine model of allergic
asthma, ovalbumin-challenged Abcg1−/− mice displayed
increased airway neutrophils and IL-17, which are im-
plicated in severe forms of asthma [46]. These findings
suggest that ABCG1 plays a critical role in regulating
the host defence response in the lung. Overall, results
from murine models provide strong evidence for the
critical role of ABCG1 in maintaining cellular lipid
homeostasis and controlling pulmonary inflammation.
Inflammatory profile of ABCG1-knockout mice
Amongst the myriad of inflammatory cytokines and
chemokines released in asthma and COPD, several have
also been identified in Abcg1-knockout mice. Levels of
the inflammatory cytokines tumour necrosis factor
(TNF)-α and IL-1β were markedly elevated in lungs of
Abcg1-deficient chow-fed mice [19]. TNF-α is
expressed in multiple lung cell types, including macro-
phages, lymphocytes, mast cells and ASM cells, and
promotes oxidative damage that subsequently activates
NF-κB and AP-1. Results of this activation include re-
cruitment of adhesion molecules, lymphocytes, and
other inflammatory cytokines, and increased airway
hyperresponsiveness [50]. IL-1β has been shown to
cause inflammation, airway fibrosis, bronchiolar thick-
ening and mucus metaplasia – features that are prom-
inent in COPD and asthma. Furthermore, IL-1β
enhanced production of matrix metalloproteinases
(MMP)-9 and −12 in neutrophils and macrophages of
murine airways respectively [51]. MMPs that degrade
extracellular matrix are overexpressed in patients with
COPD and asthma, and have been associated with
airway inflammation and remodelling [52]. Elevated
levels of MMP-8 and MMP-12 have also been reported
in lungs of Abcg1−/− mice [19]. Alveolar macrophages
also play a pivotal role in orchestrating the inflamma-
tory processes in COPD and asthma by secreting nu-
merous pro-inflammatory cytokines and chemokines
[3]. However, they also secrete inhibitory mediators
such as IL-10 that dampen inflammation, but this se-
cretion is thought to be impaired in patients with
asthma [53]. These activities were reflected in the
alveolar macrophages of Abcg1−/− mice, with Wojtik
and coauthors reporting significantly elevated pro-
inflammatory IL-1, IL-6 and IL-12 levels, and decreased
expression of the anti-inflammatory cytokine IL-10
[48]. Another study indicated that following an asthma
allergen challenge in Abcg1−/− mice, airway neutrophil
and IL-17 levels were elevated compared to wild-type
[46]. Although it was not specified which IL-17 subtype
was elevated, a separate study showed that IL-17A con-
tributes to glucocorticoid-insensitivity by decreasing
the activity of histone deacetylase-2, an enzyme that
normally mediates the anti-inflammatory effects of gluco-
corticoids [54]. Taken together, evidence from Abcg1−/−
mouse models suggest that disruption to ABCG1 activity
results in a phenotype reflective of inflammatory lung
disease.
ABCG1 and pulmonary surfactant homeostasis
ABCG1 deficiency has been identified in patients with
pulmonary alveolar proteinosis (PAP), a condition char-
acterised by pulmonary surfactant accumulation [18].
Pulmonary surfactant is produced in lamellar bodies of
ATII pneumocytes, and degraded by alveolar macro-
phages. Studies in chow-fed Abcg1−/− mice showed accu-
mulation of ATII pneumocytes that were enlarged and
engorged with surfactant-rich lamellar bodies, suggesting
abnormal surfactant clearance. Esterified cholesterol
levels were also elevated in alveolar macrophages, which
occurred despite increased Abca1 expression, which was
thought to be due to compensatory upregulation. The
authors hypothesised that ABCG1 disruption in both
these cell types resulted in defective lipid/surfactant se-
cretion, thereby resulting in compensatory cell hyper-
trophy and severe pulmonary lipidosis [16]. In 90% of
PAP cases, autoantibodies that neutralise granulocyte
macrophage-colony stimulating factor (GM-CSF) impair
alveolar macrophage maturation, consequently hindering
their ability to clear surfactant [55]. Thomassen and col-
leagues recognised that both PAP patients and GM-CSF-
knockout mice demonstrate surfactant accumulation in
alveolar macrophages, and ABCG1 deficiency, despite
increased ABCA1 activity [18]. Induction of ABCG1 ex-
pression via LXRα was able to reverse intracellular lipid
accumulation and restore lung compliance in GM-CSF-
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knockout mice [56, 57]. These results demonstrate that
ABCG1 is critical for normal surfactant metabolism.
Altogether, the importance of ABCG1 in regulating
lipid levels and inflammation in the lung is clear from
murine studies, as well as the phenotype of patients with
PAP. However, the underlying mechanisms and path-
ways by which ABCG1 mediates its protective effects are
currently unclear.
ABCA3
Unlike ABCA1 and ABCG1 that are expressed in mul-
tiple lung cell types, ABCA3 is exclusively expressed in
the lamellar bodies of ATII pneumocytes [58] and cru-
cial for the proper formation of lamellar bodies in these
cells [59]. Due to its intracellular expression, ABCA3
does not require an extracellular lipid acceptor. Sub-
strates of ABCA3 include phosphatidylcholine, phospha-
tidylglycerol and also cholesterol (see Table 1 and Fig. 1),
which are transported into the lamellar bodies [60, 61].
Within these organelles, phospholipids are combined
with surfactant proteins to produce pulmonary surfac-
tant, which is subsequently exocytosed into the alveolar
airspace to reduce surface tension and prevent alveolar
collapse [15, 62]. The exact mechanism of ABCA3-
mediated lipid transport remains elusive [63].
ABCA3 and its role in lipid homeostasis and pulmonary
inflammation
Dysfunctional ABCA3 disrupts lamellar body phospho-
lipid export, causing respiratory distress syndrome
(RDS), and pediatric and adult interstitial lung disease
[14, 60], which is a family of related conditions charac-
terised by inflammation and fibrosis of the pulmonary
interstitium [60]. RDS typically affects neonates, and is
caused by surfactant deficiency that results in alveolar
collapse, hypoxaemia and pulmonary oedema [14], hence
this condition is often lethal. Inflammation accompany-
ing RDS is fuelled by neutrophils and cytokines that are
likely controlled via the NF-κB pro-inflammatory signal-
ling pathway [64]. Corticosteroids can be used for their
ability to stimulate surfactant phospholipid synthesis in
surviving infants, but can have significant side effects.
These compounds have also been found to upregulate
ABCA3 expression and modulate transcription factors
including NF-κB in chronic inflammatory lung diseases
[58, 65]; these may be additional mechanisms by which
they facilitate foetal lung maturation.
Several murine knockout studies have also confirmed
the critical role for ABCA3 in surfactant production.
Absence of mature lamellar bodies and surfactant phos-
pholipids in the alveolar space of Abca3−/− mice resulted
in surfactant deficiency and fatal respiratory failure [15,
61]. One proposed mechanism for the disrupted surfac-
tant production seen in RDS suggests that ABCA3
mutations elevate endoplasmic reticulum stress and trig-
ger apoptosis of ATII cells [62]. Elaborating on this find-
ing, a more recent study showed that ABCA3 expression
protects ATII cells from free cholesterol-induced cyto-
toxicity by exporting free cholesterol. Cells transfected
with a non-functional mutant of ABCA3, ABCA3-
Q215K, displayed excessive accumulation of cholesteryl
esters and total phospholipids. The study showed that
the excess lipids in these cells were rerouted away from
lamellar bodies towards the ER, where the subsequent
lipid accumulation resulted in endoplasmic reticulum
stress and thus ATII apoptosis [60]. There is also in-
creasing evidence that ATII cell dysfunction and surfac-
tant abnormalities are implicated in the pathogenesis of
COPD. Surfactant dysfunction is thought to contribute
to airway resistance, oxidative stress, inflammation and
increased protease activity that promotes tissue remodel-
ling [66]. A mouse model expressing a common ABCA3
mutation observed in patients with diffuse parenchymal
lung disease, the ABCA3E292V mutation, reported spon-
taneous lung remodelling in these mice with an
emphysema-like phenotype [67]. However, no clinically
significant ABCA3 mutations have been identified in
COPD patients as yet [68].
Evidence is currently limited with respect to a poten-
tial role for ABCA3 in inflammation, despite suggestions
that it may be involved in transport of cholesterol. Bron-
choalveolar lavage cells from lungs of Abca3−/− mice
showed no statistically significant increase in expression
of inflammatory cytokines, although measurements were
only made for five cytokines [69]. In patients with
ABCA3 mutations, levels of the representative cytokine
IL-8 were significantly elevated in ATII cells as com-
pared to normal cells [17]. It is unknown whether the in-
crease in IL-8 was due to lipid accumulation within the
ATII cells.
An alternate mechanism by which ABCA3-deficiency
may lead to inflammation may be due to the associated
reduction in the secretion of surfactant proteins. The
hydrophilic collectins SP-A and SP-D have immuno-
modulatory functions, and have been suggested to re-
duce inflammation in the lungs by enhancing
phagocytosis of apoptotic cells and pathogens, and inhi-
biting T-cell function. A deficiency in their secretion
has been associated with the pathogenesis of COPD
and asthma, although previous attempts at administer-
ing surfactants to asthma patients had mixed results
[70–72]. Chiba and colleagues also demonstrated that
both SP-A and phosphatidylglycerol in surfactant have
anti-inflammatory effects [72]. Since it is clear that
ABCA3 is critical for lamellar body formation, it is pos-
sible that ABCA3 indirectly modulates lung inflammation
by helping to form the organelles that are necessary to
produce these anti-inflammatory surfactant components.
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In summary, our understanding of a role for ABCA3
in regulating lung lipid levels and inflammation is not as
expansive as that for ABCA1 and ABCG1. Its role in the
lung has been well defined in the context of surfactant
production, however how it modulates pulmonary in-
flammation warrants further investigation.
Statins as alternate therapy for inflammatory lung disease
Recently, attention has been given to statins to explore
their effect on lung inflammation in asthma and COPD.
In addition to their lipid-lowering effects, statins have
pleiotropic anti-inflammatory, antioxidant and anti-
proliferative properties. In vivo studies in rodents have
been promising, with simvastatin attenuating tobacco-
induced infiltration of macrophages, neutrophils and
leukocytes into the airways [9], and reducing the expres-
sion of macrophages, neutrophils, eosinophils, MMPs
and various inflammatory cytokines in bronchoalveolar
lavage fluid in ovalbumin-induced allergic asthma [73].
However, the benefits of statins in humans with inflam-
matory lung conditions have so far been inconsistent.
Observational studies in humans have shown that statins
can reduce exacerbation and mortality rates, and im-
prove symptom control in patients with asthma and
COPD [8, 74, 75]. Furthermore, a randomised placebo-
controlled study in 12 COPD patients reported signifi-
cantly reduced levels of inflammatory cells and media-
tors in the lung following atorvastatin treatment,
although this did not translate into improved lung
function [76]. On the other hand, one randomised double-
blind crossover trial found no anti-inflammatory activity
in asthma patients given simvastatin [77], while a large-
scale randomised placebo-controlled trial in 884 patients
concluded that simvastatin was ineffective in reducing ex-
acerbations in moderate-to-severe COPD [78]. Two sys-
tematic reviews have reported statistically insignificant
improvements in symptom control or lung function in
asthma patients, however data did support statin-
associated reductions in airway inflammation [79, 80].
A possible explanation for the inconsistent effects of
statins may be their negative effects on ABC trans-
porter expression. It has been well established that sta-
tin treatment in cells negatively affect ABCA1 and
ABCG1 expression via an LXR dependent mechanism
[81, 82]. This may have offset some of the benefits asso-
ciated with their cholesterol-lowering and pleiotropic
anti-inflammatory effects.
Conclusions
Although much of our understanding of the function of
ABC lipid transporters has been derived from studies in
the context of cardiovascular disease, there has been in-
creasing interest in their activities in the lung. Studies
utilising murine knockout models have reported
congruent results that support the crucial roles of
ABCA1 and ABCG1 in maintaining lipid homeostasis in
alveolar macrophages, ASM cells, and ATI and ATII
pneumocytes. Furthermore, many studies have affirmed
a role of ABCG1 in protecting against lung inflamma-
tion, whereas positive, albeit less evidence is available for
ABCA1, and thus this is an area requiring further investi-
gation. Human pathologies such as RDS demonstrate a
clear link between ABCA3 dysfunction and lipid disrup-
tion in ATII cells. Although a direct relationship between
ABCA3 and inflammation has yet to be established, cur-
rently evidence suggests it plays an indirect role via the se-
cretion of surfactant proteins. Statins have also shown
mixed clinical benefits in improving outcomes in asthma
and COPD, and any positive effects have been attributed
to their pleiotropic anti-inflammatory activity. Other po-
tential therapies such as inhaled apoA-I mimetic peptides
have been suggested but so far not tested. Overall, ABC
transporters are a promising area to further explore in the
search for more effective therapies for inflammatory lung
diseases.
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